Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL
Condition(s):CD19-positive ALLLast Updated:March 11, 2020Unknown status
Hide Studies Not Open or Pending
Condition(s):CD19-positive ALLLast Updated:March 11, 2020Unknown status
Condition(s):Multiple MyelomaLast Updated:February 27, 2019Unknown status
Condition(s):Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell LymphomaLast Updated:March 16, 2017Unknown status
Condition(s):Multiple MyelomaLast Updated:March 1, 2021Recruiting
Condition(s):Acute Ischemic StrokeLast Updated:October 4, 2019Unknown status
Condition(s):Acute Ischemic Stroke; Stroke, Acute; Stroke, IschemicLast Updated:April 1, 2021Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.